Cumulative incidence of relapse or TRM of recipients of CB or BM among patients with AML or ALL. For patients with AML, the cumulative incidence of (A) relapse (CB vs BM = 31% vs 24% at 2 years, P = .068) and (C) TRM (CB vs BM = 33% vs 22% at 2 years, P = .004) was higher in CB recipients. For patients with ALL, the cumulative incidence of relapse (B) was higher in CB recipients with marginal significance (CB vs BM = 31% vs 24% at 2 years, P = .085), but the incidence of TRM (D) was similar in CB and BM recipients (CB vs BM = 24% vs 25% at 2 years, P = .83).